Tofacitinib enhances remyelination and improves myelin integrity in cuprizone-induced mice

References

• Wallin MT, Culpepper WJ, Nichols E, et al. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019;18(3):269–285.
   PubMed Web of Science ®Google Scholar
• Loma I, Heyman R. Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol. 2011;9(3):409–416.
   PubMed Web of Science ®Google Scholar
• Lubetzki C, Zalc B, Williams A, et al. Remyelination in multiple sclerosis: from basic science to clinical translation. Lancet Neurol. 2020;19(8):678–688.
   PubMed Web of Science ®Google Scholar
• Lassmann H, Bradl M. Multiple sclerosis: experimental models and reality. Acta Neuropathol. 2017;133(2):223–244.
   PubMed Web of Science ®Google Scholar
• Praet J, Orije J, Kara F, et al. Cuprizone-induced demyelination and demyelination-associated inflammation result in different proton magnetic resonance metabolite spectra. NMR Biomed. 2015;28(4):505–513.
   PubMed Web of Science ®Google Scholar
• Vega-Riquer JM, Mendez-Victoriano G, Morales-Luckie RA, et al. Five decades of cuprizone, an updated model to replicate demyelinating diseases. Curr Neuropharmacol. 2019;17(2):129–141.
   PubMed Web of Science ®Google Scholar
• Pfeiffer F, Frommer-Kaestle G, Fallier-Becker P. Structural adaption of axons during de- and remyelination in the Cuprizone mouse model. Brain Pathol. 2019;29(5):675–692.
   PubMed Web of Science ®Google Scholar
• Refolo V, Stefanova N. Neuroinflammation and glial phenotypic changes in alpha-synucleinopathies. Front Cell Neurosci. 2019;13:263.
   PubMed Web of Science ®Google Scholar
• Schmitz T, Chew LJ. Cytokines and myelination in the central nervous system. ScientificWorldJournal. 2008;8:1119–1147.
   PubMedGoogle Scholar
• Castellazzi M, Ligi D, Contaldi E, et al. Multiplex matrix metalloproteinases analysis in the cerebrospinal fluid reveals potential specific patterns in multiple sclerosis patients. Front Neurol. 2018;9:1080.
   PubMed Web of Science ®Google Scholar
• Constantinescu CS, Farooqi N, O’Brien K, et al. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol. 2011;164(4):1079–1106.
   PubMed Web of Science ®Google Scholar
• Sen Almuslehi Gyengesi, et al. Suppression of the peripheral immune system limits the central immune response following cuprizone-feeding: relevance to modelling multiple sclerosis. Cells. 2019;8(11):1314.
   Web of Science ®Google Scholar
• Zhou Y, Leng X, Luo S, et al. Tolerogenic dendritic cells generated with tofacitinib ameliorate experimental autoimmune encephalomyelitis through modulation of Th17/treg balance. J Immunol Res. 2016;2016:5021537–5021513.
   PubMed Web of Science ®Google Scholar
• Yoshida H, Kimura A, Fukaya T, et al. Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation. Biochem Biophys Res Commun. 2012;418(2):234–240.
   PubMed Web of Science ®Google Scholar
• Percie Du Sert N, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. BMC Vet Res. 2020;16(1):242.
   PubMed Web of Science ®Google Scholar
• Zhen W, Liu A, Lu J, et al. An alternative cuprizone-induced demyelination and remyelination mouse model. ASN Neuro. 2017;9(4):1759091417725174.
   Web of Science ®Google Scholar
• Gilli F, Royce DB, Pachner AR. Measuring progressive neurological disability in a mouse model of multiple sclerosis. J Vis Exp. 2016;2016(117):54616.
   Google Scholar
• Hagemeyer N, Boretius S, Ott C, et al. Erythropoietin attenuates neurological and histological consequences of toxic demyelination in mice. Mol Med. 2012;18(4):628–635.
   PubMed Web of Science ®Google Scholar
• Dieckmann-Schuppert A, Schnittler HJ. A simple assay for quantification of protein in tissue sections, cell cultures, and cell homogenates, and of protein immobilized on solid surfaces. Cell Tissue Res. 1997;288(1):119–126.
   PubMed Web of Science ®Google Scholar
• Baecher-Allan C, Kaskow BJ, Weiner HL. Multiple sclerosis: mechanisms and immunotherapy. Neuron. 2018;97(4):742–768.
   PubMed Web of Science ®Google Scholar
• Benveniste EN, Liu Y, McFarland BC, et al. Involvement of the janus kinase/signal transducer and activator of transcription signaling pathway in multiple sclerosis and the animal model of experimental autoimmune encephalomyelitis. J Interferon Cytokine Res. 2014;34(8):577–588.
   PubMed Web of Science ®Google Scholar
• Massoud F, Ismail II, Al-Hashel JY, et al. CNS demyelination during tofacitinib therapy: first report. Mult Scler Relat Disord. 2020;46:102568.
   PubMed Web of Science ®Google Scholar
• Egwuagu CE, Larkin IIIJ. Therapeutic targeting of STAT pathways in CNS autoimmune diseases. JAKSTAT. 2014;2(1):e24134.
   Google Scholar
• Lee JS, Kim SH. Dose-dependent pharmacokinetics of tofacitinib in rats: influence of hepatic and intestinal First-Pass metabolism. Pharmaceutics. 2019;11(7):318.
   PubMed Web of Science ®Google Scholar
• Fukuyama T, Tschernig T, Qi Y, et al. Aggression behaviour induced by oral administration of the janus-kinase inhibitor tofacitinib, but not oclacitinib, under stressful conditions. Eur J Pharmacol. 2015;764:278–282.
   PubMed Web of Science ®Google Scholar
• Pasquini LA, Calatayud CA, Bertone Uña AL, et al. The neurotoxic effect of cuprizone on oligodendrocytes depends on the presence of pro-inflammatory cytokines secreted by microglia. Neurochem Res. 2007;32(2):279–292.
   PubMed Web of Science ®Google Scholar
• Kang Z, Liu L, Spangler R, et al. IL-17-induced act1-mediated signaling is critical for cuprizone-Induced demyelination. J Neurosci. 2012;32(24):8284–8292.
   PubMed Web of Science ®Google Scholar
• Baaklini CS, Rawji KS, Duncan GJ, et al. Central nervous system remyelination: roles of glia and innate immune cells. Front Mol Neurosci. 2019;12:225.
   PubMed Web of Science ®Google Scholar
• Göbel K, Ruck T, Meuth SG. Cytokine signaling in multiple sclerosis: lost in translation. Mult Scler. 2018;24(4):432–439.
   PubMed Web of Science ®Google Scholar
• Mirshafiey A, Asghari B, Ghalamfarsa G, et al. أهمية الأنزيمات المعدنية المحللة للبروتين في تطور مرض التصلب العصبي المتعدد و. علاجه [The significance of matrix metalloproteinases in the immunopathogenesis and treatment of multiple sclerosis]. Sultan Qaboos Univ Med J. 2014;14(1):13–25.
   Google Scholar
• Boziki M, Grigoriadis N. An update on the role of matrix metalloproteinases in the pathogenesis of multiple sclerosis. Med Chem. 2018;14(2):155–169.
   PubMed Web of Science ®Google Scholar
• Uhm JH, Dooley NP, Oh LYS, et al. Oligodendrocytes utilize a matrix metalloproteinase, MMP-9, to extend processes along an astrocyte extracellular matrix. Glia. 1998;22(1):53–63.
   PubMed Web of Science ®Google Scholar
• Asahi M, Wang X, Mori T, et al. Effects of matrix metalloproteinase-9 gene Knock-Out on the proteolysis of blood–brain barrier and white matter components after cerebral ischemia. J Neurosci. 2001;21(19):7724–7732.
   PubMed Web of Science ®Google Scholar
• Avolio C, Ruggieri M, Giuliani F, et al. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol. 2003;136(1–2):46–53.
   PubMed Web of Science ®Google Scholar
• Boyle DL, Soma K, Hodge J, et al. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis. 2015;74(6):1311–1316.
   PubMed Web of Science ®Google Scholar
• Zou M, Zhang X, Xu C. IL6-induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3'-diindolylmethane in ovarian cancer cells. Cell Oncol. 2016;39(1):47–57.
   Web of Science ®Google Scholar
• Xuan L, Han F, Gong L, et al. Ceramide induces MMP-9 expression through JAK2/STAT3 pathway in airway epithelium. Lipids Health Dis. 2020;19(1):1–9.
   PubMed Web of Science ®Google Scholar
• Seif F, Khoshmirsafa M, Aazami H, et al. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal. 2017;15(1):23.
   PubMedGoogle Scholar
• Liu Y, Holdbrooks AT, De Sarno P, et al. Therapeutic efficacy of suppressing the JAK/STAT pathway in multiple models of experimental autoimmune encephalomyelitis. J Immunol. 2014;192(1):59–72.
   PubMed Web of Science ®Google Scholar
• Liu Y, Gibson SA, Benveniste EN, et al. Opportunities for translation from the bench: therapeutic intervention of the JAK/STAT pathway in neuroinflammatory diseases. Crit Rev Immunol. 2015;35(6):505–527.
   PubMed Web of Science ®Google Scholar